Reducing the risk of failure: biomarker-guided trial design

被引：12
|
作者：
Townsend, Michael J. [1 ]
Arron, Joseph R. [2 ]
机构：
[1] Genentech Inc, Biomarker Discovery OMNI, 1 DNA Way, San Francisco, CA 94080 USA
[2] Genentech Inc, Immunol Discovery, 1 DNA Way, San Francisco, CA 94080 USA
来源：
NATURE REVIEWS DRUG DISCOVERY | 2016年 / 15卷 / 08期
关键词：
D O I：
10.1038/nrd.2016.124
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Drug candidates may fail in clinical trials for many reasons. Biomarker-guided clinical trial design can mitigate the risk of failure and enable more informative clinical experiments regardless of outcomes.
引用
收藏
页码：517 / 518
页数：2
相关论文
共 50 条
  • [31] A Novel Biomarker-guided Immunomodulatory Approach for the Therapy of Sepsis
    Trapnell, Bruce C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 180 (07) : 585 - 586
  • [32] Biomarker-guided antibiotic stewardship in neonatology: time for implementation?
    Van Wyk, Lizelle
    Lloyd, Lizel G.
    PEDIATRIC RESEARCH, 2025,
  • [33] Biomarker-guided therapy in chronic heart failure: A meta-analysis of randomized controlled trials
    Felker, G. Michael
    Hasselblad, Vic
    Hernandez, Adrian F.
    O'Connor, Christopher M.
    AMERICAN HEART JOURNAL, 2009, 158 (03) : 422 - 430
  • [34] Biomarker-guided therapy for colorectal cancer: strength in complexity
    Anita Sveen
    Scott Kopetz
    Ragnhild A. Lothe
    Nature Reviews Clinical Oncology, 2020, 17 : 11 - 32
  • [35] Adrecizumab: an investigational agent for the biomarker-guided treatment of sepsis
    Deniau, Benjamin
    Takagi, Koji
    Asakage, Ayu
    Mebazaa, Alexandre
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2021, 30 (02) : 95 - 102
  • [36] Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma
    Yang, Haitang
    Xu, Duo
    Schmid, Ralph A.
    Peng, Ren-Wang
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [37] Neonatal Outcomes after Maternal Biomarker-Guided Preterm Birth Intervention: The AVERT PRETERM Trial
    Hoffman, Matthew K.
    Kitto, Carrie
    Zhang, Zugui
    Shi, Jing
    Walker, Michael G.
    Shahbaba, Babak
    Ruhstaller, Kelly
    DIAGNOSTICS, 2024, 14 (14)
  • [38] Biomarker-guided antibiotic therapy-strengths and limitations
    Nora, David
    Salluh, Jorge
    Martin-Loeches, Ignacio
    Povoa, Pedro
    ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (10)
  • [39] Biomarker-guided stratification of autoimmune patients for biologic therapy
    Ivison, Sabine
    Des Rosiers, Christine
    Lesage, Sylvie
    Rioux, John D.
    Levings, Megan K.
    CURRENT OPINION IN IMMUNOLOGY, 2017, 49 : 56 - 63
  • [40] Biomarker-guided de-escalation of empirical therapy is associated with lower risk for adverse outcomes
    Schuetz, Philipp
    Mueller, Beat
    INTENSIVE CARE MEDICINE, 2014, 40 (01) : 141 - 141
12345